Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children (Nissle 1917)
Urinary tract infections (UTIs) are a common and costly cause of doctor visits for children. Frequent UTIs trigger kidney damage that leads to serious diseases like high blood pressure, pregnancy complications, and kidney failure. Treating UTIs with preventative antibiotics has not shown improvement of the risk of these diseases, and contributes to the growing public health issue of antibiotic resistant bacteria. Bacteria that cause UTIs originate from the bowel. In an effort to reduce the number of UTIs, investigators want to exchange the bacteria living in our bowels for a more harmless variety.
Hypothesis and specific aims:
Investigators hypothesize a probiotic comprised of a probiotic bacteria will change the bowel bacteria, thereby reducing the numbers of infection-causing bacteria, thus reducing frequency of UTIs in healthy patients with recurrent UTIs and those patients with urinary tract problems that require use of catheters to empty their bladders.
Aim 1: Investigators plan to challenge infection-causing bacteria like Pseudomonas species, Enterococcus species, and Klebsiella species to live in the same environment with the probiotic bacteria to see how the numbers of each bacteria change.
Aim 2: Investigators will culture bacteria that live on urinary catheters and then challenge them to live in the same environment as the probiotic bacteria.
This novel treatment prevents UTIs by exchanging a patient's bowel bacteria for a harmless bacteria and reduces the use of antibiotics overall in the community.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Targeted Pathogen Replacement With Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children|
- Ability of Nissle 1917 to adversely affect the growth in vitro of identified uropathogens [ Time Frame: 2 years ] [ Designated as safety issue: No ]Uropathogens obtained from discarded clinical samples will be challenged to live in the same environment as the probiotic, Nissle 1917. Colonies of uropathogens and Nissle 1917 will be counted as a measure of the more successful organism as well as, zone of inhibition will be measured in co-cultures.
Biospecimen Retention: Samples Without DNA
|Study Start Date:||July 2012|
|Study Completion Date:||June 2014|
|Primary Completion Date:||June 2014 (Final data collection date for primary outcome measure)|
In vitro, Nissle 1917's ability to adversely affect the growth of uropathogens associated with urinary catheters and those with a known GI resevoir will be measured.
Drug: Nissle 1917
Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01696227
|United States, Ohio|
|Nationwide Children's Hospital|
|Columbus, Ohio, United States, 43206|
|Principal Investigator:||Elizabeth J Lucas, MD||Nationwide Children's Hospital|